An Investigation into the Potential of SarAr for Use in 64Cu Radioimmunotherapy

Article

<< Previous

Next >>

Contents Vol 62(10)

doi:10.1071/CH09369

An Investigation into the Potential of SarAr for Use in ⁶⁴Cu Radioimmunotherapy

Nadine Di Bartolo ^A ^B, Suzanne V. Smith ^A ^D, Eric Hetherington ^A, Alan Sargeson ^B ^C

^A Australian Nuclear Science and Technology Organisation (ANSTO), PMB 1, Menai, NSW 2234, Australia.
^B Research School of Chemistry, Australian National University, Canberra, ACT 0200, Australia.
^C Deceased.
^D Corresponding author. Email: svs@ansto.gov.au





	PDF (296 KB) $25



	Export Citation

Print

Australian Journal of Chemistry 62(10) 1261–1270 http://dx.doi.org/10.1071/CH09369
Submitted: 30 June 2009 Accepted: 13 August 2009 Published online: 13 October 2009

Abstract

The B72.3 monoclonal antibody was radiolabelled with ¹²³I, and with ¹¹¹In and ⁶⁴Cu, using DTPA and SarAr, respectively. Their biodistribution in tumour-bearing nude mice was used to calculate the dosimetry of their respective therapeutic analogue, using ¹³¹I, ⁹⁰Y, ⁶⁷Cu, and ⁶⁴Cu. Two dosimetry models were used: one using the classical approach and a second model that takes into consideration the chemical stability of the radiolabelling methods employed and the biological clearance of each radioimmunoconjugate. Results clearly show that the ⁶⁴Cu-SarAr-B72.3 could be used as a therapeutic agent and, theoretically, be at least as effective as any of the other therapeutic radionuclides currently studied, such as ¹³¹I, ⁹⁰Y, and ⁶⁷Cu.